PAREDRINE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Paredrine, and when can generic versions of Paredrine launch?
Paredrine is a drug marketed by Pharmics and is included in one NDA.
The generic ingredient in PAREDRINE is hydroxyamphetamine hydrobromide. There are two drug master file entries for this compound. Additional details are available on the hydroxyamphetamine hydrobromide profile page.
Summary for PAREDRINE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 68 |
| Patent Applications: | 1,693 |
| DailyMed Link: | PAREDRINE at DailyMed |
US Patents and Regulatory Information for PAREDRINE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmics | PAREDRINE | hydroxyamphetamine hydrobromide | SOLUTION/DROPS;OPHTHALMIC | 000004-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
